All In Biotech

NDA 209589 · Ferring Pharms INC

Clenpiq

Citric Acid, Magnesium Oxide, Sodium Picosulfate · Oral · Calculi Dissolution Agent; Anti-coagulant

Last checked: Nov 20, 2026Latest source record: Aug 29, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Nov 28, 2017

Approved uses

3

Original approval plus efficacy supplements

Registered trials

516

148 Phase 3, 44 recruiting

FAERS reports

726

156 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 15, 2026.

CLENPIQ is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. CLENPIQ ® is a combination of sodium picosulfate, a stimulant laxative, and magnesium oxide and anhydrous citric acid, which form magnesium citrate, an osmotic laxative, indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients ages 9 years and older. ( 1 )

Mechanism: Sodium picosulfate is hydrolyzed by colonic bacteria to form an active metabolite: bis-(p-hydroxy-phenyl)-pyridyl-2-methane, BHPM, which acts directly on the colonic mucosa to stimulate colonic peristalsis. Magnesium oxide and citric acid react to create magnesium citrate in solution, which is an osmotic agent that causes water to be retained within the gastrointestinal tract.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CLENPIQ · CITRIC ACID 12GM/BOT; MAGNESIUM OXIDE 3.5GM/BOT; SODIUM PICOSULFATE 10MG/BOT · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Citric Acid" as an intervention, any sponsor and status, largest first.

All 516 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective196
  • nausea107
  • vomiting91
  • diarrhoea62
  • incorrect dose administered56
  • headache53
  • dizziness35
  • product packaging difficult to open35
  • product taste abnormal34
  • therapeutic product effect incomplete33
  • malaise32
  • abdominal distension29

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2018100
201990
202045
202117
202289
2023134
2024118
202590
202643

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Clenpiq (Sod Picosulf/Mag Ox/Citric Ac)

2024 spending

$26.3M

Beneficiaries

149,396

154,263 claims

Per beneficiary

$176

$0.49 per unit

View as table
YearSpending
2020$4,099,468
2021$11,805,906
2022$19,613,505
2023$33,188,399
2024$26,315,591

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 506 on PubMed

Sponsor: Ferring Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.